HLA-B*58:01 Genotyping to Prevent Cases of DRESS and SJS/TEN in East Asians Treated with Allopurinol

Abstract

Background and objective

East Asians exposed to the urate-lowering drug allopurinol have a predilection for severe cutaneous drug reactions such as drug-induced hypersensitivity syndrome or drug reaction with eosinophilia and systemic symptoms (DRESS) and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Screening is recommended in patients of East Asian descent for the presence of HLA-B*58:01 prior to allopurinol initiation to avoid these complications. Utilization rates of the HLA-B*58:01 predictive screening test within the Greater Vancouver area, which has a population composed of 40.1% people of East Asian descent, are unknown.

Measures

We identified cases of DRESS or SJS/TEN due to allopurinol using the Vancouver General Hospital dermatology consult service database. We next compared the frequency in which the HLA-B*58:01 screening test was ordered since 2012 to the estimated frequency of new prescriptions for allopurinol prescribed for the management of gout among the East Asians.

Results

We report 5 cases of East Asian patients exposed to allopurinol for management of gout between 2012 and 2016, who developed DRESS (4 patients) or SJS/TEN (1 patient). All were of HLA-B*58:01 genotype, representing preventable cases. The HLA-B*58:01 test was ordered 6 times in 2012, whereas the estimated number of new cases of allopurinol-prescribed gout among patients of East Asian descent during that time period was 13. For 2012, testing was ordered for only 46% of at-risk patients.

Conclusion

We continue to observe cases of severe cutaneous drug reactions among high-risk individuals due to allopurinol exposure. The HLA-B*58:01 screening test for allopurinol hypersensitivity is underutilized in our geographic area.

Keywords

allopurinol HLA genotyping East Asians severe cutaneous adverse drug reactions

Get full access to this article

View all access options for this article.

References

Stern

. Reducing life-threatening allopurinol hypersensitivity. JAMA Intern Med. 2015;175:1558-1558.

Jutkowitz

Dubreuil

Kuntz

Choi

. The cost-effectiveness of HLA-b*5801 screening to guide initial urate-lowering therapy for gout in the United States. Semin Arthritis Rheum. 2017;46(5):594-600. doi:10.1016/j.semarthrit.2016.10.009

Husain

Reddy

Schwartz

. DRESS syndrome: part I. Clinical perspectives. J Am Acad Dermatol. 2013;68:693.e1-14; quiz 706-708.

Schwartz

McDonough

Lee

. Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69:173.e1-13; quiz 185-186.

Hung

S-I

Chung

Liou

et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102:4134-4139.

Khanna

Fitzgerald

Khanna

et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64:1431-1446.

Khanna

Fitzgerald

et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64:1447-1461.

Kardaun

Sidoroff

Valeyrie-Allanore

et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156:609-611.

Bastuji-Garin

Fouchard

Bertocchi

Roujeau

Revuz

Wolkenstein

. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149-153.

10.

Wortmann

. Gout and hyperuricemia. Curr Opin Rheumatol. 2002;14:281-286.

11.

Terkeltaub

. Clinical practice. Gout. N Engl J Med. 2003;349:1647-1655.

12.

Auböck

Fritsch

. Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis. Br Med J (Clin Res Ed). 1985;290:1969-1970.

13.

Hershfield

Callaghan

Tassaneeyakul

et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013;93:153-158.

14.

Saito

Stamp

Caudle

et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2016;99:36-37.

15.

C-H

Chung

Wen

et al. Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions. J Rheumatol. 2017;44:835-843.

16.

Park

D-J

Kang

Lee

et al. Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea. Arthritis Care Res (Hoboken). 2015;67:280-287.

17.

Lee

M-HH

Stocker

Williams

Day

. HLA-B*5801 should be used to screen for risk of Stevens-Johnson syndrome in family members of Han Chinese patients commencing allopurinol therapy. J Rheumatol. 2013;40:96-97.

18.

T-M

Tsai

Chen

et al. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ. 2015;351:h4848.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.17 MB

HLA-B*58:01 Genotyping to Prevent Cases of DRESS and SJS/TEN in East Asians Treated with Allopurinol—A Canadian Missed Opportunity

Abstract

Background and objective

Measures

Results

Conclusion

Keywords

Get full access to this article

References

Supplementary Material